Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBD SARS-CoV-2 HBsAg VLP vaccine phase 1/2 trial
ACTRN12620001308987Phase 2Terminated
- Sponsor
- Accelagen
- Start
- Dec 2020
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of RBD SARS-CoV-2 HBsAg VLP COVID-19 vaccine, sponsored by Accelagen. Started Dec 2020; status: terminated.
02
Drugs
RBD SARS-CoV-2 HBsAg VLP COVID-19 vaccine
Beyond the preview
Go deeper on ACTRN12620001308987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001308987.